title: Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma.
abstract: Denileukin diftitox plus rituximab was evaluated in relapsed/refractory B-cell non-Hodgkin lymphoma patients. Of the 38 evaluable patients, 30 (80%) were rituximab-refractory. The overall response rate (ORR) was 32%, with six complete responses (CR) and six partial responses (PR). The median time to progression for responders was 8 months (range: 2-36+); two patients with rituximab-refractory follicular lymphoma were in CR at 25 and 36+ months. The ORR was 55% (4 CRs, 2 PRs) in 11/14 patients with rituximab-refractory follicular lymphoma, and 100% in the three patients with rituximab-sensitive tumour. Most toxicities were low grade and transient, and myelotoxicity was uncommon.
authors.affiliation: Department of Hematologic Malignancies, Nevada Cancer Institute, Las Vegas, NV 89135, USA. ndang@nvcancer.org
authors.forename: Nam H
authors.initials: NH
authors.lastname: Dang
authors.forename: Luis
authors.initials: L
authors.lastname: Fayad
authors.forename: Peter
authors.initials: P
authors.lastname: McLaughlin
authors.forename: Jorge E
authors.initials: JE
authors.lastname: Romaguara
authors.forename: Fredrick
authors.initials: F
authors.lastname: Hagemeister
authors.forename: Andre
authors.initials: A
authors.lastname: Goy
authors.forename: Sattva
authors.initials: S
authors.lastname: Neelapu
authors.forename: Felipe
authors.initials: F
authors.lastname: Samaniego
authors.forename: Pamela L
authors.initials: PL
authors.lastname: Walker
authors.forename: Michael
authors.initials: M
authors.lastname: Wang
authors.forename: Maria A
authors.initials: MA
authors.lastname: Rodriguez
authors.forename: Ann T
authors.initials: AT
authors.lastname: Tong
authors.forename: Barbara
authors.initials: B
authors.lastname: Pro
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004167:Diphtheria Toxin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000473:pathology; D008224:Lymphoma, Follicular / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D012008:Recurrence; D000069283:Rituximab; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D004167:Diphtheria Toxin; D007376:Interleukin-2; D011993:Recombinant Fusion Proteins; C078456:denileukin diftitox; D000069283:Rituximab